Adenosine and adenosine analogs induce analgesia in humans and presumed antinociception in animal models when administered both systemically and intrathetally. In the present investigation in rats, we studied the effects of intrathecally administered adenosine analogs, with or without systemic coadministration of an adenosine antagonist (theophylline), on substance P (SP) and calcitonin gene-related peptide (CGRP) concentrations in cerebrospinal fluid (CSF). In parallel, nociceptive reflex testing (tail immersion latency) and motor function were evaluated. The potent unselective adenosine receptor agonist N-ethylcarboxamide-adenosine (NECA) and the relatively adenosine A, receptor selective agonist R-phenylisopropyl-adenosine (R-PIA) both reduced SP-like immunoreactivity (-LI) by 50%, whereas CGRP-LI remained unchanged. There was a dose-dependent increase in tail immersion latency. This effect was present without motor impairment when R-PIA was administered in doses up to 5 nmol. R-PIA (lo-100 nmol), as well as l-100 run01 of the unselective agonist NECA, produced dosedependent motor impairment. The reduction of SP-LI as well as the behavioral effects were reversed by theophylline. We conclude that SP reduction in CSF, which possibly reflects reduced SP turnover after adenosine receptor stimulation, provides an additional possible mechanism of action for the analgesic effects of adenosine. Implications: We studied the interactions between the known pain mediator substance P and substances with effects similar to the endogenous pain modulator adenosine in rats. The results suggest that the pain-reducing effect of adenosine is, at least partly, due to a reduction of substance P in cerebrospinal fluid.
Adenosine and adenosine analogs induce analgesia in humans and presumed antinociception in animal models when administered both systemically and intrathetally. In the present investigation in rats, we studied the effects of intrathecally administered adenosine analogs, with or without systemic coadministration of an adenosine antagonist (theophylline), on substance P (SP) and calcitonin gene-related peptide (CGRP) concentrations in cerebrospinal fluid (CSF). In parallel, nociceptive reflex testing (tail immersion latency) and motor function were evaluated. The potent unselective adenosine receptor agonist N-ethylcarboxamide-adenosine (NECA) and the relatively adenosine A, receptor selective agonist R-phenylisopropyl-adenosine (R-PIA) both reduced SP-like immunoreactivity (-LI) by 50%, whereas CGRP-LI remained unchanged. There was a dose-dependent increase in tail immersion latency. This effect was present without motor impairment when R-PIA was administered in doses up to 5 nmol. R-PIA (lo-100 nmol), as well as l-100 run01 of the unselective agonist NECA, produced dosedependent motor impairment. The reduction of SP-LI as well as the behavioral effects were reversed by theophylline. We conclude that SP reduction in CSF, which possibly reflects reduced SP turnover after adenosine receptor stimulation, provides an additional possible mechanism of action for the analgesic effects of adenosine. Implications: We studied the interactions between the known pain mediator substance P and substances with effects similar to the endogenous pain modulator adenosine in rats. The results suggest that the pain-reducing effect of adenosine is, at least partly, due to a reduction of substance P in cerebrospinal fluid. (Anesth Analg 1997; 85:627-32) A denosine is one of several endogenous compounds that have been attracting a growing interest concerning their role in nociception. Intravenous (IV), small-dose adenosine infusion in patients reduces postoperative pain and analgesic demand (1). Reduction of secondary hyperalgesia after cutaneous inflammation has also been shown (2). In patients suffering long-lasting, painful mononeuropathy with allodynia, symptoms of neuronal hyperexcitability were decreased by systemic infusion of adenosine (3). Intrathecal (IT) administration of the relatively adenosine A, receptor selective agonist R-phenylisopropyladenosine (R-PIA) provided long-lasting pain reduction in one patient suffering severe tactile allodynia (4).
In animal models for acute nociception, adenosine and its analogs have demonstrated inhibitory effects in nociceptive reflex tests (5). In rats with experimentally induced mononeuropathy (6), both systemic and IT administration of R-PIA reduced scratching and tactile hypersensitivity of the neuropathic hindlimb, which possibly reflects antinociception (7, 8) .
The mechanisms of the analgetic effects of adenosine have been studied in animal models. Data indicate that the pain inhibitory effects are mediated via specific cell surface-associated adenosine A, receptors in the spinal cord dorsal horn (5,9). Adenosine A, receptors in the spinal cord are linked to the inhibition of adenyl cyclase activity (5). In neurophysiological studies, adenosine inhibited synaptic transmission in the substantia gelatinosa of the spinal cord dorsal horn via hyperpolarization of the postsynaptic membrane (10). A presynaptic action via Cazt current inhibition has also been suggested (5,lO) . Another possible spinal mechanism is that the inhibitory effects of adenosine are potentiated by tachykinins (11, 12 vitro models, interaction between substance P (SF') and adenosine with respect to changes in tachykinin receptor binding (13), and adenosine-mediated inhibition of the release of SP as well as calcitonin gene-related peptide (CGRP) from capsaicin-sensitive primary afferents in the rat dorsal horn has been shown (14). The transmission and modulation of nociceptive input in the dorsal horn of the spinal cord is a most complex process in which several neurotransmitters have been implicated (15). Among the endogenous peptides shown to play a central role are SP and CGRP. Colocalized with excitatory amino acids in small diameter primary afferent neurons, they facilitate the transmission of nociceptive input (15). The C-fiber release of SP and excitatory amino acids after noxious stimulation is reduced by exogenous opioids, and IT administration of SP antagonists also inhibits presumed pain behavior in animal models (15). CGRP is also released in the dorsal horn after noxious stimuli (15). A possible effect of CGRP is that by inhibiting the endopeptidases responsible for peptide degradation, it may increase the spread and, thereby, the effects of SP (16).
The aim of this study was to investigate the effect of adenosine receptor stimulation on the concentrations of SP-like immunoreactivity (-LI) and CGRP-LI in cerebrospinal fluid (CSF) in rats. We also set out to study the effects on a behavioral parameter with possible relevance to nociception (tail immersion latency) as well as motor function. Further, the effect of systemic coadministration of an adenosine antagonist (theophylline) was evaluated.
Methods
All experiments were performed with the approval of the local animal ethics committee. The experimental protocol was divided into four parts (I-IV), as illustrated in Table 1 . Male Sprague-Dawley rats (ALAB, Sollentuna, Sweden) weighing 250-280 g were used for Parts I-III. In Part IV, a similar but not identical strain of male rats (SD, also from ALAB) was used, because the breeder at this time had modified its strain of rats and could no longer deliver animals identical to those used in Parts I-III. All treatment procedures were performed by an investigator blinded to the intervention.
Part I
The animals were anesthetized for surgery by intraperitoneal injection of 350 mg/kg chloral hydrate (KEBO, SpHnga, Sweden). A catheter (PE 10, outer diameter 0.61 mm) was inserted through the atlantooccipital membrane into the spinal subarachnoid space, with the tip in the lumbar region (17). The animals were allowed 7 days for recovery and showed no signs of spinal cord injury. The rats were kept in separate cages with free access to food and water. Two days after surgery, the IT position of the catheter was confirmed by the injection of 7 PL of lidocaine (50 mg/ mL, Xylocaine; Astra, Siidertalge, Sweden) followed by 15 PL of saline. This produced a temporary paralysis of the hindlimbs. The catheter was used for all IT drug administration but not for aspiration of CSF in these animals.
Parts II-IV
A simpler procedure for IT drug administration in alert animals was used in these parts (18). Drugs were injected IT using a stainless steel 26-gauge cannula inserted directly into the subarachnoid space between the third and fourth, or fourth and fifth, lumbar vertebrae. The IT position was confirmed by the occurrence of a tail flick. Systemic drugs (theophylline 50 mg/kg or saline) were administered IV via a tail vein using a 26-gauge cannula.
Drugs, Peptide Analyses, and Behavioral Studies
All IT drugs were administrated in a volume of 10 PL (followed by 15 PL of saline when an implanted IT catheter was used). The adenosine receptor antagonist and agonists used were: theophylline 20 mg/mL (ACO, Stockholm, Sweden), R-PIA (Boehringer-Mannheim Biochemica, Ingelheim, Germany), N-ethylcarboxamideadenosine (NECA; Astra). Because of its limited solubility in water, R-PIA was dissolved in hydrochloric acid and then buffered to a pH of 7.0 using sodium hydroxide. The solution was then diluted in saline to the required concentration in each case.
CSF SP-LI and CGRP-LI were analyzed using radioimmunoassay methods. For SP-LI antiserum-SP2, which reacts equally with SF' and SP-sulfoxide but not with other tachykinins, was used. Intra-and interassay coefficients of variation were 7% and ll%, respectively (19). CGRP-LI was analyzed using antiserum-CGRPRS. High-performance liquid chromatographypurified Iiz5 -Histidyl rat CGRP was used as radioligand. Cross-reactivity toward rat CGRP I and II was 100% and 120%, respectively. Intra-and interassay coefficients of variation were 8% and 14%, respectively (20). All behavioral tests were performed by the same investigator. Tail immersion latency was tested as described by Woolf et al. (21) . Cut of time was 15 s. Motor score was evaluated using the method described by Karlsten et al. (22) , using four grades: 1 = no motor impairment, 2 = partial paresis of the hindlimbs, 3 = full paresis of the hindlimbs, 4 = full paresis of the hindlimbs and some impairment in the front limbs.
Experimental Schedule Part I. These animals (n = 6-8 per group) were used to study the effect on tail immersion latency and motor score after the IT injection of 1,5,10,30 or 100 nmol of R-PIA via the implanted catheter (NECA was not used in this part of the study). These behavioral variables were assessed repeatedly during the 90 min after injection (see Table 1 ).
Part II. This part (n = 7-8 per group) was designed to analyze the CSF concentrations of SP-LI and CGRP-LI after the IT administration of 1,5, or 10 nmol of R-PIA and NECA, respectively. Saline was used as control. Using the time of IT drug administration as the starting point, tail immersion latency and motor score tests were performed at 30 min. Sixty minutes after IT drug administration, the animals were anesthetized with intraperitoneal chloral hydrate. A 26-gauge steel cannula was used to stereotactically cannulate the fourth ventricle (20). CSF was aspirated (up to 200 PL or until blood appeared in the cannula). The animals were then killed. CSF SP-LI and CGRP-LI were analyzed.
Part III. The reversibility of the effects found in Part II were tested. The adenosine antagonist theophylline (50 mg/ kg) or an equal volume of saline was injected IV 5 min after the IT injection of 10 nmol of R-PIA, NECA, or saline (n = 7-10 per group). The time of administration of the adenosine antagonist was chosen to produce high serum concentrations in the time interval when maximal antinociceptive effects of R-HA and NECA have been shown to occur (22) and still leave the animal time to recover from the IV injection before behavioral assessment (25 min). The schedule for behavioral assessments and peptide analyses were the same as those in Part II.
Part IV. This part consisted of tests similar to those in Part III, but they were performed on a modified strain of rats (n = 8 per group), and they used 10 or 30 nmol of R-PIA, NECA, or saline IT in combination with systemic theophylline or saline, as described above.
Statistics
Motor score results are shown as median and quartiles. All other results are shown as mean +-SD. The Mann-Whitney U-test was used in all statistical evaluations. P values co.05 were considered significant. In Part i, the results from all the saline-treated animals used in Parts II and III (n = 26) were used as control group (control animals from Part IV were excluded because they were of a slightly different strain). In all other parts, the results were compared with the salinetreated animals in the same part of the study.
Results
The CSF concentrations of SP-LI and CGRP-LI are shown in Table 2 . The concentration of SP-LI in CSF was significantly reduced in both R-PIA-and NECAtreated animals. When Sprague-Dawley rats were used, this effect was significant after 10 nmol of R-PIA or NECA. In the SD rats used in Part IV, the reduction was significant after 30 nmol but not after 10 nmol. Data are compared with all saline-treated animals in Parts II and III. *P < 0.01. Lt. inj. = intrathecal injection.
Coadministration of theophylline abolished the reduction of SP-LI. No statistically significant differences in the CSF concentration of CGRP-LI were found in any group of animals.
The results of-the behavioral assessments of Part I (IT R-PIA, l-100 nmol) are shown in Figure 1 , and the results from Part III (10 nmol of R-PIA or NECA with or without systemic theophylline) are shown in Table  3 . The Sprague-Dawley rats had behavioral test results similar to those of SD strain when saline-treated animals were compared (data not shown). All doses of NECA (l-100 nmol) and the larger doses of R-HA (lo-100 nmol) caused motor deficiencies with long onset latency and duration that outlasted the observation period. In Part II, the motor score 30 min after the IT injection of 1, 5, or 10 nmol of R-PIA was normal (Grade 1) in all animals, whereas the same doses of NECA resulted in median motor scores of 1 (l-1.5), 1.5 (l-2.5) (P < 0.05), and 3.5 (3-4) (P < 0.01).
The increase in tail immersion latency after both R-PIA and NECA administration was dose-dependent. The prolongation of tail immersion latency had a shorter onset latency and duration than the motor effects discussed above. IV theophylline alone shortened the tail immersion latency, and when it was combined with IT adenosine analogs, the changes in motor performance and tail immersion latency were either blocked or markedly attenuated.
The results of the behavioral as well as peptide-LI tests were consistent throughout all parts of the study. The results of some measurements in some groups are not shown because they add no further information.
Discussion
The major novel finding of this study is that SP-LI, but not CGRP-LI, is reduced in CSF in neurologically intact rats after the IT administration of adenosine analogs. This effect was seen regardless of whether the IT administered drug was a nonselective (NECA) or adenosine A, receptor-selective agonist (R-PIA). In addition, the changes in an acute nociceptive threshold test (tail immersion latency) suggest antinociception. Changes in both behavioral and CSF neuropeptide-11 concentrations after adenosine receptor stimulation were antagonized by the systemic administration of an adenosine receptor antagonist (theophylline). In fact, theophylline treatment alone induced significant hyperreactivity in the tail immersion test. The mechanism for this response may involve loss of modulation of nociception by endogenous adenosine, but possibly also involves other unrelated effects of theophylline (23).
The site of action for the observed behavioral as well as neurochemical effects could involve spinal and supraspinal mechanisms. The SP-LI and CGRP-LI in this study are based on CSF collected from the fourth ventricle, and could result from SP and CGRP released in any part of the central nervous system. SP is found in sensory neurons in the dorsal horn and also within the brain, primarily in striatonigral pathways, the hypothalamus, and the limbic forebrain (24). A supraspinal spread and effect of spinally administered adenosine analogs is possible. Such supraspinal sites of action could be reached either by rostra1 spread in the CSF or, although less likely, via the systemic circulation. Because the adenosine analogs were administered at a lumbar spinal level, and based on earlier studies, we primarily discuss possible interactions on the spinal cord level. The preferential paraparesis after both NECA and the larger doses of R-PIA also indicate major distribution at the spinal cord level. The reduction by half of the SP-LI concentration in CSF after IT adenosine analog administration indicates that SP turnover, involving both inhibition of SP release and increased elimination, is altered in the central nervous system. This reduction of SP could be of importance for the changes in tail immersion latency, which suggest analgesia. The changes in SP-LI were found when doses of adenosine analogs larger than those needed to induce detectable tail immersion latency changes, were administered.
It is also noteworthy that the obvious dose-dependence of the changes in motor performance and acute nociceptive reflex testing could not be shown when SF'-LI was evaluated. It is possible that local changes in SP in the spinal cord, involved in the observed modulation of the response to nociceptive stimulation, occur without significant changes in the concentration of SP-LI in the CSF collected. Evidence to support this may be gathered by direct measurements of spinal cord peptide content. CSF was collected 60 minutes after the IT injection of the adenosine agonist, when a presumed analgetic effect was still present but when little or no motor impairment was observed as an effect of R-PIA in the doses that produced a significant SP-LI reduction. This suggests that the peptides in CSF at this time reflected neuronal release during the interval when R-PIA produced antinociception but mild or nonexistent motor impairment.
The difference in SP-LI levels found when SD rats were used might be explained by the use of a modified strain of animals, which possibly reflects differences in sensitivity to adenosine receptor stimulation.
The mechanism of action for the demonstrated adenosine receptor-mediated reduction of SP-LI and its relevance to antinociception remains speculative. Some information about the influence of adenosine on SP and CGRP release from the spinal cord is available. As judged from in vitro data on rat spinal cord slices (after chronic nerve damage), adenosine and its analogs fail to antagonize stimulated SP release (25). However, this finding does not rule out the possibility that adenosine receptor stimulation modifies the SP turnover in intact animals. The CSF concentration of CGRP-LI remained unchanged in all groups of the present study in which CSF was analyzed, which indicates that adenosine does not affect CGRP turnover in the unchallenged intact nervous system. This finding is also in contrast to an in vitro study by Santicioli et al. (14), in which adenosine-induced inhibition of the release of both CGRP and SP from capsaicinsensitive primary afferent terminals in the rat dorsal horn was shown. The differences could be explained by the use of in vitro models instead of intact animals, as used in the present study, in which both ascending and descending pathways are intact and may influence the overall response to adenosine receptor stimulation. Different anatomical sites of sample collection could also account for this difference.
Dorsal horn SP, released by noxious but not by nonnoxious stimuli, originates from primary afferent, intrinsic, and descending spinal cord neurons (15, 26) . The role of SP in hyperalgesia and neuronal hyperexcitability has been extensively studied (27) . It has been suggested that SP facilitates the excitatory amino acidinduced activation of the N-methyl o-aspartate receptor via NK-1 receptor stimulation.
The resulting increased excitability of dorsal horn sensory neurons (wind-up) is probably an important mechanism in long-lasting hyperalgesia and pain. This proposed role for SP is supported by the results from behavioral studies using SP antagonists in animal models of peripheral inflammation (15, 27) . Numerous reports also suggest the involvement of CGRP in spinal cord transmission of nociception (cc 15), but the role of CGRP is not as well studied as that of SP due to a shortage of selective antagonists.
The finding of changes in SP-LI but not CGRP-LI concentrations in CSF after IT adenosine analog administration indicates a selective rather than a general inhibitory effect of adenosine receptor stimulation. Both similarities and differences with other aspects of spinal cord modulation of nociception can be found in the results of the present study. The adenosine receptormediated reduction of CSF SP-LI, but not of CGRP-LI levels, shows a similarity with the y-aminobutyric acid (GABA) system. In chronic monoarthritic rats, the GABAg receptor antagonist (CGP 36742) was shown to enhance SP release, whereas CGRP was unaffected (28). This suggests a tonic inhibitory effect on spinal SP turnover mediated via GABA, receptors. This proposed inhibition of SP but not CGRP release by both GABA-and adenosine-mediated mechanisms is in contrast to the action of endogenous opioids, because naloxone enhanced both SP and CGRP release in the same chronic pain model (28). However, it should be noted that the model using intact animals in the present study is different from the above-referenced studies using monoarthritic rats. The dose-dependent increase in tail immersion latency after adenosine analog administration has a much earlier onset and different duration than the motor deficit seen in animals after IT NECA and larger doses of IT R-PIA. When these motor deficits do occur, they do not seem to increase tail immersion latency, which suggests that this sacral segment nociceptive reflex test is little affected by the loss of motor function at the lumbar level. This study confirms the results of a previous study (22) that shows these dosedependent effects and the duration of IT administration of adenosine receptor agonists with regard to acute nociceptive threshold testing and motor function. The observed differences in behavioral effects after administration of the relatively adenosine A, receptor-selective agonist R-PIA and the potent but nonselective agonist NECA are well known (I$ 5). Because no adenosine A, receptor-selective agonists or unselective antagonists was used, the observed effects could be adenosine A, receptor-and/or adenosine A, receptor-mediated.
The observed differences could also be caused by variable penetration times into different parts of the spinal cord, as well as the result of involvement of different adenosine receptors, as previously discussed (22).
In conclusion, IT adenosine receptor agonist treatment reduces SP-LI levels in CSF and causes dosedependent behavioral effects, which suggest antinociception. This novel interaction between adenosine receptor stimulation and SP turnover warrants further evaluation of adenosine agonist action on spinal cord modulation of nociception. 
